BioXcel Therapeutics Inc (BTAI)

2.11 -0.02 (-0.94%) USD  |  NASDAQ  |  May 15, 15:46
More

BioXcel Therapeutics Cash from Financing (Quarterly): 26.63M for March 31, 2024

Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Upgrade now.
Date Value
March 31, 2024 26.63M
December 31, 2023 2.123M
September 30, 2023 0.00
June 30, 2023 0.25M
March 31, 2023 24.15M
December 31, 2022 0.05M
September 30, 2022 30.05M
June 30, 2022 66.14M
March 31, 2022 0.00
December 31, 2021 0.00
September 30, 2021 0.071M
June 30, 2021 101.52M
March 31, 2021 0.852M
December 31, 2020 0.233M
September 30, 2020 187.03M
Date Value
June 30, 2020 0.271M
March 31, 2020 59.83M
December 31, 2019 0.095M
September 30, 2019 17.82M
June 30, 2019 -0.079M
March 31, 2019 0.001M
December 31, 2018 -0.058M
September 30, 2018 0.021M
June 30, 2018 -0.026M
March 31, 2018 55.59M
December 31, 2017 1.231M
September 30, 2017 0.791M
June 30, 2017 0.63M
March 31, 2017 0.431M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

-0.079M
Minimum
Jun 2019
187.03M
Maximum
Sep 2020
25.85M
Average
0.5615M
Median

Cash from Financing (Quarterly) Benchmarks

Cormedix Inc -0.0971M
Bristol-Myers Squibb Co 14.64B
Amicus Therapeutics Inc -13.31M
Insmed Inc 3.022M
InfuSystems Holdings Inc 0.632M

Cash from Financing (Quarterly) Related Metrics

Cash from Operations (Quarterly) -17.71M
Free Cash Flow -120.36M
Free Cash Flow Per Share (Quarterly) -0.5736
Free Cash Flow to Equity (Quarterly) -18.74M
Free Cash Flow Yield -192.1%